The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

Persistent human papillomavirus (HPV) infection causes almost all cervical cancers. Cervical cancer screening is recommended ...

In fact, 25 percent of cervical cancer diagnoses occur in women over the age of 65, and cervical cancers diagnosed in this ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Indigenously developed (Human papillomavirus) HPV test kits for cervical cancer screening were launched on Wednesday (April 23, 2025). The test kits have been developed under the Department of ...

The study titled 'Validation of Indigenous Human Papillomavirus Tests for Cervical Cancer Screening in India (i-HPV)' validated indigenously developed, rapid, point-of-care, RTPCR-based HPV ...

CERVICAL cancer is the fourth most common cancer in Jamaica, and the second leading cause of cancer-related deaths among Jamaican women. But it is considered a preventable disease, and ...

Women in Alabama are more likely to die from cervical cancer than most other states in the nation, yet few young people are getting vaccinated to help prevent the disease. Less than 40% of 14-18 ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

A new study finds that Schistosoma haematobium infection, and its treatment, can activate cancer-related genes in the cervix, ...